Evidence map›Paper›PMID 40615691›Full record

ArticleOncogene2025

Increased antiandrogen enzalutamide sensitivity via altering prostate cancer stem cell traits through modulating the androgen receptor-mediated CDR1/circCDR1-AS/miR-1290/BMP4 signaling.

Diwei Huo, Minggui Si, Kexin Yu, Xiaoxue Fang, Hongbo Liu, Donglong Li, Zhengxing Chen, Jinguo Li, Ruicong Xu, Xinwang Su and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Diwei Huo *Department of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Minggui Si *Department of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Kexin Yu *Department of Pharmacogenomics, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xiaoxue Fang *Operating Room, The Fourth Hospital of Harbin Medical University, Harbin, China.
Hongbo LiuDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Donglong LiDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Zhengxing ChenDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Jinguo LiDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Ruicong XuDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Xinwang SuDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Yongfeng DuDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Xuebin MaDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Xunwei WangDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Pengbo LiDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China.
Huike YangDepartment of Anatomy, Harbin Medical University, Harbin, China. huikeyang@hrbmu.edu.cn.
Xiujie ChenDepartment of Pharmacogenomics, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China. chenxiujie@ems.hrbmu.edu.cn.
Keliang WangDepartment of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, China. wangkeliang@hrbmu.edu.cn.ORCID http://orcid.org/0009-0008-8709-9168

Funding

Harbin Medical University (HMU) HMUMIF-22007National Natural Science Foundation of China (National Science Foundation of China) 82172782Natural Science Foundation of Heilongjiang Province LH2021H040
6 · The paper itself

Abstract

While the recent FDA-approved antiandrogen enzalutamide (Enz) might prolong the survival of castration-resistant prostate cancer (CRPC) patients by an additional 4.8 months, most patients eventually might still develop Enz resistance within 6-12 months. Although few genes have been linked to Enz resistance in prostate cancer (PCa), the detailed mechanism(s) are still underinvestigated. Here, we found that Enz might function by altering androgen receptor(AR)-mediated CDR1/circCDR1-AS/miR-1290/BMP4 signaling to modulate PCa stem cells (CSCs) to increase Enz resistance. Mechanistic analysis revealed that Enz/AR signaling can transcriptionally regulate CDR1 expression by reducing binding to androgen response elements (AREs) on the CDR1 5' promoter to alter circCDR1-AS expression. Enz/AR/CDR1/circCDR1-AS signaling might then increase BMP4 expression by altering miR-1290 expression, which involves direct binding to the 3' UTR of BMP4 mRNA. Preclinical studies using a CWR22Rv1 xenograft mouse model and integrative analysis of GEO cohort data further demonstrated that targeting this newly identified Enz/AR/CDR1/circCDR1-AS/miR-1290/BMP4 signaling pathway with miR-1290, circCDR1-AS-shRNA, or BMP4-shRNA may help develop novel therapies to combat Enz resistance at the later stage of CRPC.

Indexed as

Androgen AntagonistsBenzamidesNeoplastic Stem CellsPhenylthiohydantoinProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAnimalsBone Morphogenetic Protein 4Cell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMaleMiceMicroRNAsAndrogen AntagonistsAR protein, humanBenzamidesBMP4 protein, humanBone Morphogenetic Protein 4enzalutamideMicroRNAsNitrilesPhenylthiohydantoinReceptors, Androgen

Identifiers

PMID40615691
PMCPMC12375499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.